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Models can be used to plan, evaluate, and improve programs for animal disease control.
In Germany, a nationwide compulsory program to eradicate Bovine viral diarrhea (BVD)
is in force since January 2011. As it is associated with substantial expenditures, the
program is currently under revision. To provide the basis for a science-based decision on
the future course of BVD control in Germany, we evaluated 13 scenarios (sc1-13) with
respect to the chance of reaching freedom from disease and their economic implications
for a period of 20 years (2011–2030). To simulate the impact of different control strategies
on disease dynamics, a disease spread model was developed. To estimate the effects
of a transient infection (TI) on animal level, a gross margin analysis was performed. To
assess the value of cattle that died prematurely, a valuation model was used. Finally,
an economic model was developed to perform a cost-benefit analysis and to compare
each control scenario with a baseline setting with no BVD control. Costs comprised
the expenditures for diagnostics, vaccination, preventive culling, and trade restrictions.
Benefits were animal and production losses avoided by having control measures in place.
The results show that reducing the PI prevalence on animal level to 0% is only feasible
in scenarios that combine antigen or antibody testing with compulsory vaccination. All
other scenarios, i.e., those based exclusively on a “test and cull” approach, including
the current control program, will, according to the model, not achieve freedom of BVD
by 2030. On the other hand, none of the scenarios that may lead to complete BVD
eradication is economically attractive [benefit-cost ratio (BCR) between 0.64 and 0.94].
The average direct costs of BVD in Germany are estimated at 113 million Euros per year
(34–402 million Euros), corresponding to 28.3 million Euros per million animals. Only the
concepts of the former and the current national BVD control program (“ear tag testing
and culling”) may reduce the BVD prevalence to 0.01% with an acceptable BCR (net
present value of 222 and 238 million Euros, respectively, with a BCR of 1.22 and 1.24).
Keywords: bovine viral diarrhea, disease control, economic analysis, cost-benefit analysis, agent-based model,
dairy cattle
Gethmann et al. Economic Model of BVD in Germany
INTRODUCTION
Bovine viral diarrhea (BVD) is an important infectious disease
in cattle with a major economic impact that varies within and
between countries (1, 2). Most of the economic damage is caused
by a lower reproductive performance in dairy cattle, including
reduced conception rate, abortion and reduced milk yield.
Depending on the stage of pregnancy at the time of infection,
vertical BVD transmission may result in abortion/stillbirth,
congenital defects, growth retardation or the birth of persistently
infected (PI) calves, which are often small and unthrifty, have
increased susceptibility to other diseases and may eventually die
from mucosal disease (3). Horizontal transmission can occur
by direct or indirect contact with virus-shedding animals. The
causative agent, BVD virus (BVDV), belongs to the genus
Pestivirus of the family Flaviviridae and is divided into two
genotypes: Pestivirus A (previously BVDV-1) and Pestivirus B
(previously BVDV-2) (4). Although the existence of Pestivirus B
has been confirmed in Germany (5), the predominant genotype
in the country is Pestivirus A.
A number of countries in the European Union, e.g., Spain,
do not monitor BVD at the national level (6). However,
most countries have implemented voluntary or mandatory
BVD control programs, which can lead to a significant
decline in the PI prevalence (7). The programs differ in the
way PI animals are detected, and in allowing or excluding
vaccination. Some successful programs combine the test and
cull strategy with vaccination, e.g., in Belgium, Ireland and
Scotland (8). Others were successful without using vaccination,
e.g., those implemented in Scandinavian countries, Austria and
Switzerland (9–14). The economic impact of BVD and different
control strategies has recently been reviewed in a number of
publications (14–16).
According to the German statistical office (Destatis) and the
Federal Office for Agriculture and Food, in 2017 there were 12.37
million heads of cattle in the country, including 4.2 million dairy
cows, distributed in 143 thousand cattle farms. In Germany,
the first voluntary BVD control program was developed in the
late 1980s by the federal state of Lower Saxony (17). Central
elements were the identification and elimination of PI animals
and the systematic vaccination of all female offspring (18). Later,
other federal states launched their own BVD control programs,
on either a voluntary (e.g., Bavaria, North Rhine Westphalia,
Lower Saxony) or a compulsory basis (e.g., Saxony-Anhalt) (19).
However, the programs differed between the federal states and
participation was at least in the beginning voluntary, with the
consequence that little progress was achieved (20). There were
also drawbacks in PI-free herds that had become seronegative
and thus fully susceptible in an environment where infectious
pressure of BVDV was high (21).
On 3November 2004, BVD became a notifiable animal disease
in Germany and on January 1, 2011, a nationwide compulsory
BVD control program was started (22). At that time, the PI
prevalence in Germany was at about 0.5% on animal level (23)
and a limited proportion of the population was vaccinated against
BVD. Consequently, all animals had to be tested for BVDV or
its genome. The new regulations of 2011 introduced the testing
of all newborn calves combining the cattle ear tag application
with the sampling of a small ear tissue plug, which was subjected
to BVDV testing (24). PI animals have to be eliminated (either
immediately culled or slaughtered within seven days). It is also
mandatory to test animals prior to movement if they have
not been assigned a BVD status. Only cattle that have tested
negative for BVDV (“unsuspicious animals”) may be traded.
If an animal tests positive for BVDV, it is either removed
(usually slaughtered) or retested after 6 weeks to rule out a
transient infection. The German BVD control program has
always allowed the use of vaccines, since they are considered
a useful addition for preventing the formation of PI calves.
In Germany, one modified live and several inactivated BVD
vaccines are currently registered and can be used in different
vaccination schemes. Since 2009, all BVD vaccinations and
test results are recorded at the individual animal level in the
national animal identification database (“Herkunftssicherungs-
und Informationssystem für Tiere,” HIT), which is used for the
registration of cattle holdings, all cattle individually, and for
movements of cattle. Reliable BVD data are available since mid-
2011. Based on the time point and the results of the BVD
tests, an algorithm integrated into HIT calculates the individual
BVD status: (i) without status; (ii) unsuspicious, i.e., antibody
negative or mother of negative calf; (iii) first test positive; (iv) PI
animal, i.e., two consecutive positive tests, or positive test without
confirmation, or a calf of a PI mother.
Between the onset of mandatory testing in January 2011
and December 2016, more than 34 million animals were tested,
registered in the HIT database and assigned a BVD status. The
proportion of PI affected farms (animals) was reduced from
3.44% (0.48%) in 2011 to 0.16% (0.02%) in 2016. Although no
recent studies are available, the seroprevalence in Germany is still
assumed at 10-25%, depending on the region (25). The national
BVD control strategy is currently under revision. The following
alternatives to the current control policy are under discussion:
(1) Stop BVD control and monitoring1 including a strict non-
vaccination policy. (2) Continue controlling and monitoring
BVD as laid down in the national regulation implemented
from 2011 to 2016. (3) Proceed as in (2) with additional trade
restrictions for BVD-affected cattle farms. (4) Continue BVD
control as laid down in the current BVD regulation (antigen-
detection by ear tag). (5) Proceed as in (4) with additional
antibody testing (AbT) in individual or pooled serum/plasma
samples from young stock between 9 and 12 months (so
called “Jungtierfenster”) (26, 27) and voluntary vaccination. (6)
Proceed as in (5) with additional compulsory vaccination. In
this study, we evaluated 13 scenarios including the current BVD
control policy, different combinations of the above-mentioned
alternatives, and a baseline scenario (no BVD control) with
respect to the chance of disease eradication and the economic
implications in a period of 20 years (2011–2030).
1Control means, a pre-defined control measure is carried out (e.g., culling, trade
restriction, quarantine), if a BVDV positive animal is detected. Monitoring is
a systematic measurement of animal health, where a positive result does not
necessarily lead to action.
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MATERIALS AND METHODS
Scenarios
Starting with the baseline scenario without any BVD control
(sc1), we developed 12 alternative scenarios and simulated the
course of BVD from 2011 onwards. In sc2, we simulated the
former BVD control program that was in place in Germany
2011–2016. In sc3, we simulated the control program that is
currently in place. In sc4, we simulated the immediate cessation
of BVD control on July 1, 2017. The other nine scenarios
were deduced from the current epidemiological situation and
represent potential options for future BVD control based on
various combinations of measures.
Each scenario is a chronological order of strategies; each
strategy consists of a combination of measures (e.g., ear tag and
vaccination; Table 1). All 13 scenarios start with the strategy
“no BVD control” (sc1). By contrast, scenarios sc2-13 include
the former BVD regulation as implemented on January 1, 2011.
While sc2 represents only the continuation of the former BVD
regulation (in place from 2011 to 2016), scenarios sc3-13 go
beyond sc2 by including also themeasures foreseen in the current
BVD regulation as implemented on June 27, 2016. While sc3
represents the continuation of the current BVD regulation, sc4-
13 implement different further strategies in the model from July
1, 2017 onwards.
Scenario 1 (sc1) reflects the basic situation, in which no
control program is in place, i.e., no efforts are made to detect
or remove PI animals. Thus, no vaccination expenses or other
preventive expenditures are included in the economic model.
This scenario is hypothetical, since Germany has implemented
BVD control measures for a long time. Scenario sc1 was included
to compare different intervention scenarios with a “baseline”
scenario that does not include any intervention.
Scenario 2 (sc2) was designed according to the control
program that was in place in Germany between 2011 and 2016
(former BVD regulation). This program included obligatory
antigen screening (ear tag) in newborn calves (<7 days) and
the removal of PI animals within 60 days after confirmation of
a BVD positive test result. The strategy also included voluntary
vaccination and individual antigen testing in adult animals before
trading them.
Scenario 3 (sc3) combines the strategy of the former BVD
regulation with the control program, which is in place in
Germany since June 27, 2016 (new BVD regulation). Similar
to sc2, it includes antigen screening (ear tag) in newborn
calves (<7 days) as well as individual antigen testing in adult
animals before trading and voluntary vaccination. In contrast
to sc2, sc3 includes the removal of PI animals within 40
days (instead of 60 days in sc2) and a trade restriction of
40 days for farms after confirmation of a BVD infection in
the herd.
Scenario 4 (sc4) is similar to sc3 but assumes that BVD control
has stopped on July 1, 2017.
Scenario 5 (sc5) is similar to sc3 with the only difference that
it includes compulsory vaccination starting on July 1, 2017.
Scenarios 6 and 7 (sc6, sc7) include antigen detection after
birth or before trade (similar to sc2, sc3, and sc5). In addition,
they also include AbT, either twice a year (sc6) or once a year
(sc7) and PI removal within 40 days as well as trade restrictions
of 40 days, but no vaccination.
Scenarios 8 and 9 (sc8, sc9) are similar to sc6 and sc7 and
include AbT, either twice a year (sc8) or once a year (sc9), but in
contrast to sc6 and sc7, they include compulsory vaccination.
Scenario 10 (sc10) only includes AbT twice a year.
Scenarios 11 and 12 (sc11, sc12) represent the decision to stop
testing on July 1, 2017 and to switch to vaccination only, either
immediately (sc11) or after a transitional period (sc12).
Scenario 13 (sc13) combines the measures of AbT twice a
year and compulsory vaccination. Testing of ear tags plugs is
stopped after a transition period of 1 year (06/2018) to allow
the whole cattle population to become protected by vaccination
against BVD.
TABLE 1 | Overview of the 13 modeled BVD control scenarios.
Scenario Strategies (start) Measures
24/11/1983 01/01/2011 29/06/2016 01/07/2017
1 1 No control
2 1 2 Former regulation (ear tag)
3 1 2 3 New regulation (ear tag, trade restrictions)
4 1 2 3 1 No control
5 1 2 3 4 Ear tag, compulsory vaccination
6 1 2 3 5 Ear tag AbT 2×/year
7 1 2 3 AbT 1×/year
8 1 2 3 6 Ear tag, compulsory vaccination AbT 2×/year
9 1 2 3 AbT 1×/year
10 1 2 3 7 AbT 2×/year
11 1 2 3 8 Compulsory vaccination, stop testing Inmediate stop
12 1 2 3 Slow stop
13 1 2 3 9 Compulsory vaccination AbT 2×/year
The different colors represent different strategies. Each scenario is a chronological order of strategies; each strategy consists of a combination of measures.
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Models
The evaluation of the eradication success and profitability of
different BVD control scenarios was done in four steps. (1)
An agent-based disease spread model (DSM) was developed to
simulate the dynamics of BVD spread and immunity within the
population. (2) A gross margin analysis (GMA) was performed to
estimate the economic impact of a transient BVD infection. (3)
To estimate the value of PI animals that prematurely die of BVD,
we developed a stochastic animal valuation model (AVM). (4)
We developed an economic model and performed a cost-benefit
analysis (CBA) using the results of the DSM, GMA and AVM.
Disease Spread Model (DSM)
To simulate the dynamics of BVD in different scenarios, a
stochastic, event-driven, hierarchical agent-based disease spread
model (DSM) was developed.Within the DSM, trade was realized
using a farm manager and a market. The farm manager keeps
the size of the farms constant. When a farm has too many
animals, it will sell animals to a market, if it needs animals it
will buy animals from the market. These movements are based
on trade criteria. If there is no demand on animals with a
certain criteria, they will be slaughtered. Whenever there are
not enough animals in the market, new animals are created
(simulation of imports from EU member states). The DSM
takes into account (i) five individual disease status, namely
susceptible, transiently infected (TI), persistently infected (PI),
recovered from transient infection, and vaccinated; (ii) disease
transmission between animals, (iii) disease transmission (trade)
between farms, and (iv) the introduction of new animals into
the population. We assume that (1) recovery from natural BVD
infection leads to lifelong immunity, that (2) calves with maternal
antibodies are protected for about 6–9months after birth and that
(3) vaccination requires yearly boosting. To take the constant risk
of disease introduction through imports into account, the model
includes a trade manager and the PI prevalence of imported
animals was set at 2%. Each individual animal is simulated from
birth to death.
The following input parameters were retrieved from the DSM:
- Number of farms with no active infection (i.e., all animals
susceptible), with protected (recovered or vaccinated) animals,
and with PI animals per scenario and year;
- Number of PIs and TIs and animals that died from mucosal
disease per scenario and year;
- Number of farms and animals subject to control measures, i.e.,
number of diagnostic tests (ear tag, blood samples for PCR and
AbT), scenario and year; number of vaccinated animals and
number of vaccinations by scenario and year;
The following values from the German cattle trade database
(HIT) were used as input parameters: Number of farms and farm
size distribution, age distribution for males and females, cause of
death, age at first calving, calving interval, BVD test results, and
number of PIs and TIs between 2010 and 2017.
The simulation was run in C++ for the years 1983–2030
(total of 20,000 days). Thereof, the first 10,000 days were used
to reach a stable state in disease dynamics. After 5,000 days an
equilibrium between susceptible, recovered, PI and TI animals
was reached. The source code of the model can be accessed
in a repository (https://github.com/Yperidis/bvd_agent_based_
model). The disease spread model is described according to
Grimm et al. (28) and can be found at arXiv (29). Further details
on themodel and its validation can be found at Bassett (30). Since
our statistical software is not equipped to handle extremely large
datasets (12.4 million head of cattle, 13 different scenarios), we
first run themodel on a subset of 360,000 animals.We then scaled
the results up to the whole cattle population in Germany using a
factor of 39.2.
Gross Margin Analysis (GMA)
To estimate the effects of a transient BVD infection in terms
of production losses, a gross margin analysis (GMA) on animal
level was performed for dairy cows and heifers. To consider the
heterogeneity of cattle farms in Germany in terms of herd size
andmanagement, the GMAwas performed as a stochastic model.
All estimations are based on data of the German Association
for Technology and Structures in Agriculture (“Kuratorium für
Technik und Bauwesen in der Landwirtschaft e.V., KTBL”), the
animal health services (“Tiergesundheitsdienste”), animal disease
compensation funds of the federal states (“Tierseuchenkassen“),
Destatis, and HIT database (Table S1). The GMA was carried
out with R statistical software (31) and the packages xlsx,
ggplot2, sm, fitdistrplus, MASS, foreign, EnvStats, stats, graphics,
utils, and base. For each set of parameters, 10,000 iterations
were conducted.
We calculated the gross margin (GM) for both, healthy
animals (GMh), i.e., in absence of BVD, and for cattle with
a transient BVD infection (GMTI) by adapting the respective
variables for the calving interval, milk yield, and veterinary costs.
Direct costs incurred by a TI animal (DCTI) were then calculated
as the difference between both:
DCTI = GMh − GMTI
To quantify the average impact of TI on reproduction, we
used the calving interval (Ci). In case of BVD induced
abortion/stillbirth, the Ci was increased by a certain number
of days.
To quantify these, we first estimated the probability of the
outcome (abortion/stillbirth) on five different time periods,
including four pregnancy stages (days 1–70; 71–120; 121–180;
181–285) and the post-partum stage (days 286–385), based on
Viet (32). We then calculated the overall probability for an
animal being in a particular stage with a specific outcome
(birth of a PI calf, abortion/stillbirth, congenital defect/growth
retardation, birth of an immune calf, no influence; Table S5).
Finally, we estimated the number of days the “healthy” Ci had
been prolonged in each stage, as the average of the respective
period (Table S6).
To quantify the impact of TI on the revenues in milk sale, we
multiplied the difference between the milk yield of a “healthy”
and that of an infected cow with the average milk price. All
equations and input parameters are shown in Table S1.
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Animal Valuation Model (AVM)
To estimate the market value (vc) of PI animals that
prematurely die of BVD, we devised a stochastic animal
valuation model (AVM) based on the appraisal guidelines of the
animal health compensation fund of North-Rhine-Westphalia
governing indemnity payments for livestock (“Schätzrahmen”).
Two different equations were used (for dairy cows as well as
calves and young stock, respectively). The equations combine the
age of the animal (in months) with production, reproduction
and animal health data (Table S2). The AVM was carried out
using R statistical software (31) using the packages xlsx, pander,
ggplot2, sm, fitdistrplus, MASS, foreign, EnvStats, stats, graphics,
utils, and base.
Economic Model
To simulate the economic impact of BVD and the control
measures on national level, we developed a stochastic economic
model in @Risk for Microsoft Excel 2010 with 20,000 iterations,
covering a period of 20 years (2011–2030). For parametrization,
the results of the DSM, GMA, and AVM were used. For all other
parameters, we used empirical distributions based on literature
and expert opinion (Horst Schirrmeier, Kerstin Wernike, and
Martin Beer from the FLI, Georg Wolf from the Ludwig-
Maximilians-Universität München, and Karsten Donat from the
animal disease compensation fund Thüringen). All parameters
and equations are listed in Tables S3, S4. We differentiated
between four different age groups: calves (1–6 months), young
stock (7–18 months), heifers (females 19–28 months), and cows
(females >28 months).
Total costs of BVD
The total costs of each scenario for the 20-year study period
(2011–2030) include direct and indirect costs.
Direct costs PIs. If not discovered in time, PIs may display
clinical symptoms thus requiring veterinary treatment, and they
usually die within the first 2 years of life (33). Hence, the
direct costs incurred by a PI animal include veterinary costs and
costs incurred through premature death. The latter include the
disposal costs for a calf, young stock or cow, and the lost market
value of the animal (calculated in the animal valuation model,
see chapter 3.2.3). The costs of culling or preventive slaughter
were included in the indirect costs (as they represent a BVD
control measure).
Direct costs Tis. Transient infection with BVD may cause
production losses in all age groups. In calves and young stock,
losses include poor growth and weight loss, and were estimated
using a risk uniform distribution (Table S1). For heifers, losses
include increased calving interval and were estimated in the
GMA for heifers (Table S1). For cows, losses include increased
calving interval (Ci) and the reduced milk yield. They were
estimated in the GMA for cows (Table S1). For heifers and cows,
we took a sample from the GMA results using the RiskResample
function in @Risk.
Indirect costs of BVD. Depending on the scenario, the indirect
costs of BVD include the costs to prevent infection, i.e.,
diagnostic measures and vaccination, as well as costs to control
the disease, including culling or preventive slaughter of PIs and
trade restrictions.
Diagnostic measures: Individual BVD diagnosis can either
be done through antigen or BVDV genome detection (tissue
sampling by ear tag in calves or blood sampling in adults) or
AbT (blood sampling in young stock). Ear tags are applied by the
farmer. Hence, the costs for antigen detection in ear tags include
material (ear tags and a certain percentage of ear tag pliers)
and labor (shipping, testing and communicating test results).
In contrast to tissue samples, blood samples need to be taken
by a veterinarian. So at individual animal level, the costs for
antigen detection in blood include the costs for blood sampling
and testing (PCR). On the farm level, the costs include the herd
fee, handling, shipping, and communicating test results. Similar
to blood sampling for antigen detection, the costs for blood
sampling for AbT include on the farm level the herd fee, handling,
shipping, and communicating results. At the individual animal
level, they include costs for sampling and testing (ELISA).
Vaccination: In all six scenarios that include vaccination (sc5,
8, 9, 11, 12, 13), vaccination was planned to be compulsory for
all female animals before getting pregnant. In the remaining
seven scenarios, vaccination was not included. Depending on
the vaccination scheme, several immunizations are required. As
vaccines must only be administered by veterinarians in Germany,
vaccination costs include the herd fee charged by the veterinarian.
At the individual animal level, we accounted for the number
of immunizations per animal and the costs for the vaccine
and vaccination.
Preventive slaughter of PIs: Usually, PIs are culled or
preventively slaughtered as soon as they are discovered. The lost
revenues and costs were calculated by multiplying the number of
preventively slaughtered PI calves, young stock and cows by their
relative market value, which was assumed to be lower than the
value of an average slaughter animal.
Trade restrictions: If a BVD infected animal is detected,
cattle must not be moved from the affected premise for 40 days
according to national legislation. Non-pregnant cattle can only
leave the farm for slaughter or if the animal has been subjected
to a second test 40 days after the initial analysis at the latest.
Pregnant cattle may be moved if the animal has been subjected
to a serological test after the 150th day of gestation with a
negative result. We assumed that each affected farm would move
three pregnant and three non-pregnant dams within 40 days
of quarantine (34). This implies the following costs for these
three pregnant and three non-pregnant animals: travel 10 e,
taking blood samples 10 e, handling and shipping samples 9 e,
laboratory analysis 30 e (3 × 10 e). Hence, the movement ban
would result in 118 e (2 × 59 e) additional veterinary costs per
affected premise.
Cost-benefit analysis
A cost-benefit analysis (CBA) was conducted to evaluate the
profitability of each scenario compared with sc1 (no BVD
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control) throughout the study period (2011–2030). The CBA was
performed as described by Rushton et al. (35). It was conducted
as a stochastic simulation with the add-on @Risk 5.7 (Palisade
Corporation, Ithaca, NY, USA), performed with 10,000 iterations.
The built-in @Risk sensitivity analysis tool was used to evaluate
which input parameters had the strongest effect on the results.
The benefit-cost ratio of each scenario (BCRs) was calculated by
dividing the present value of benefits (PVBs) by the present value
















The annual benefit (By,s) of each scenario was calculated as the
difference in disease (i.e., direct) costs between sc1 (DCy,s1) and
the respective alternative scenario x (DCy,s).
By,s = DCy,s1 − DCy,s
All monetary values were expressed in Euros. Break-even points
(the point at which total cost and total revenue are equal)
were obtained from the annual results for each scenario. The
analytical objective of this part of the study was to estimate the
net present value (NPV) of different scenarios over the study
period of 20 years. To enable a comparison between past, current
and future values, all monetary flows for the benefits and costs
were discounted at a rate of 3%. For reasons of comparability,
foreign currencies referred to in the international literature were
converted into Euros using the average currency exchange rate
valid in the year of publication of the respective study.
RESULTS
Disease Spread Model
The results of the DSM have been described elsewhere (30).
According to the DSM, only scenarios that combine antigen
or antibody testing with compulsory vaccination (sc5, sc8, sc9,
sc13) are likely to reduce the PI prevalence on animal level to
0%, i.e., may lead to the eradication of BVD (Figure 1). In sc5,
the PI prevalence will reach 0% in the third quarter of 2022, in
sc8 and sc9 in the fourth quarter of 2022, and in sc13 in the
second quarter of 2023. In scenarios that include compulsory
vaccination, the prevalence of protected animals (recovered or
vaccinated) will be above 75% by 2030. Scenarios that include
antigen testing (sc2, sc3, sc6, sc7) may reduce the PI prevalence to
a value 0.01%. All other scenarios, including the control program
currently in place, are unlikely to lead to BVD eradication. In
scenarios sc4, sc10, sc11, and sc12, the PI prevalence is predicted
to stay in the range of 0.01–0.05% by 2030. In scenario sc1, the
PI prevalence will decrease gradually from 1.2 to 0.9% and the
seroprevalence (recovered animals) will go down from 64 to 47%,
FIGURE 1 | Predicted PI prevalence between 2010 and 2030 for each BVD scenario. (A) Start of the former BVD regulation (sc2). (B) Start of new BVD regulation
(sc3). (C) Start of alternative scenarios (sc4–sc13).
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while the proportion of susceptible animals will increase from 35
to 52% and the TI prevalence is predicted to stay nearly constant
at a level of 0.25–0.33%.
As soon as testing stops in scenario sc4, the PI prevalence
will rapidly rise up to 0.75% in 2019 and is predicted to decrease
then again, but a proportion of 0.33% PI animals will still remain
by 2030 (Figure 1, Table 2). Although scenarios sc11 and sc12
include vaccination, they do not combine it with testing, and will
not lead to BVD eradication according to the model predictions.
In all other scenarios, the prevalence of protected animals will be
3–7% by 2030.
Gross Margin Analysis
In cows, the direct costs of a transient infection were estimated
at 55.71 Euros per animal on average (Figure 2A). An increased
Ci of 0–60 days increased the direct costs by 0–180 Euros
(Figure 2B). A reduced milk yield of 64–76 L reduced the GM
in average by 50 Euros (Figure 2C). In heifers, the average costs
were estimated at 7.80 Euros, and for calves and young cattle
between 0 and 10 Euros (mean 5 Euros).
Animal Valuation Model
The results of the AVM are shown in Table 3. The mean value of
a cow was estimated at 1,451 Euros (Table 3).
Economic Model
The results of the economic model are listed in Table S7 (direct,
indirect, and total costs per year). Direct costs are estimated at
113 (34–402) million Euros per year. They are predicted to stay
nearly constant over time, since the PI prevalence decreases very
slowly. Table 4 details the minimum, maximum, and mean total
costs. The total costs arising from BVD in sc1 (no BVD control)
were estimated at 2.258 billion Euros. The least expensive
scenarios among those that continue with BVD control are sc12
and sc11 (stop testing and switch to vaccination, either gradually
TABLE 2 | Prevalence of PI and BVD antibody-positive animals (recovered or
vaccinated).
Scenarios Prevalence in 2030 (%)
PIs Antibody positive animals
Scenario 01 0.894 46.91
Scenario 02 0.010 4.36
Scenario 03 0.009 3.17
Scenario 04 0.317 18.93
Scenario 05* 0.000 75.49
Scenario 06 0.011 3.49
Scenario 07 0.010 3.82
Scenario 08* 0.000 75.59
Scenario 09* 0.000 75.61
Scenario 10 0.053 6.53
Scenario 11* 0.026 75.95
Scenario 12* 0.026 75.98
Scenario 13* 0.000 75.62
Scenarios that include vaccination are marked with an asterisk (*).
or immediately), followed by sc3 (ear tag and quarantine), and
sc2 (ear tag). Scenarios sc11 and sc12 generate total costs of 1.81
and 1.77 billion Euros, respectively. Similar to scenario sc4, the
majority of costs are predicted to arise in the initial years, while
from 2023 onwards both scenarios, sc11 and sc12, will become
cheaper until they are expected to level off at about 65 and 66
million Euros per year. Sc2 and sc3 are predicted to cause total
costs of 1.93 and 1.91 billion Euros, respectively. The costs of
both scenarios will level off from 2017 onwards and lead to nearly
constant sums of about 84 and 82 million Euros per year.
Seven scenarios are predicted to be more expensive than sc1.
The five most expensive scenarios all include AbT. With total
costs of 7.23 billion Euros, the most expensive scenario will be sc8
(ear tag, AbT twice a year and vaccination). From 2017 onwards,
sc8 is predicted to generate increasing costs until 2024, and from
2024 onwards, they will level off at 538 million Euros per year. As
the PI prevalence is predicted to decrease to almost 0%, all costs
are allocated to control measures, in particular antigen testing in
blood (72%), antigen testing in ear tags (13%), vaccination (11%),
and antibody testing (4%) (Figure 3).
The second most expensive scenario is sc6 (ear tag and AbT
twice a year), which is predicted to generate total costs of 3.65
billion Euros, of which 90% (3.30 billion) are allocated to disease
control. The costs of sc6, sc10, and sc7 peak in 2018 and then
almost constantly decrease until 2030. Scenario sc13 (AbT twice
a year, vaccination) is the third most expensive scenario and
is expected to generate 2.75 billion Euros costs (thereof 88%
for disease control), followed by sc9 (ear tag, AbT once a year,
vaccination, 2.7 billion Euros), sc10 (AbT twice a year, 2.68 billion
Euros), sc5 (ear tag, vaccination, 2.53 billion Euros), and sc7 (ear
tag, AbT one a year, 2.51 billion Euros).
Toward the end of the study period, the yearly costs of all
scenarios are predicted to level off at almost constant sums: The
cheapest scenario will again be scenario sc4 (36% of sc1), followed
by sc12, sc11, sc3, and sc2 (66–80% of sc1). Scenarios sc7 and
sc10 will be slightly more expensive (103–104% of sc1), followed
by sc5, sc9, sc13, and sc6 (138–171% of sc1), and sc8 is expected
to stay the most expensive scenario (535% of sc1).
The highest disease impact is predicted to occur in sc1 and sc4,
i.e., in scenarios with no control or stopping control measures
altogether (2.26 billion Euros, 100% of the total costs of sc1, and
845 million Euros, 60% of the total costs of sc4). Among the
scenarios with control, the highest disease impact is predicted to
occur in sc11 and sc12 (584 and 473 million Euros, 32 and 27% of
the total costs, respectively), followed by sc10 (427 million Euros,
16%) and sc2, sc6, sc7, sc3, and sc13 (360–324 million Euros, 10–
19%). The lowest disease impact is expected to occur in sc5, sc8,
and sc9 (280–285 million Euros, 4–11% of the total costs). All
estimates are reported as medians.
Sensitivity analysis showed that the costs for AbT had the
highest impact on the indirect costs. In scenarios without
vaccination (sc6, sc7, sc10), the number of AbT will stay constant
(∼2.8 million tests per year for sc6 and sc10 and 1.4 million tests
per year for sc7). On the other hand, the number of positive
AbT is predicted to decrease to about 8% in scenarios sc6 and
sc7, and to 12% in scenario sc10. In scenarios with vaccination
(sc8, sc9, and sc13), the number of AbT will first decrease and
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FIGURE 2 | Impact of a transient BVD infection in a dairy cow: (A) Histogram of the total losses. (B) Influence of the increased calving interval. (C) Influence of the
decreased milk yield on the losses.
stay constant from 2023 onwards (∼475.000–946.000 tests per
year). In scenarios with vaccination (sc8, sc9, sc13), the number
of BVD antibody-positive animals will remain in the range of
132,000–265,000 from 2022 onwards.
Compared to sc1, the break-even points of all scenarios were
estimated to be reached in 2017. However, only sc2, sc3, sc4, sc11,
and sc12 are predicted to stay beneficial, while the cumulative
costs of all other scenarios will rise in the following years and will
finally be higher than the benefit. Scenarios sc6, sc7, sc8, and sc10
are unlikely to result in profit from 2018 onwards, sc9 from 2021,
sc13 from 2022, and sc5 from 2023 onwards.
Table 5 lists the undiscounted and discounted benefit (B),
indirect costs (IC), benefit-cost ratio (BCR), net value (NV), and
net present value (NPV) per scenario.
The discounted BCR was estimated to range between 0.31
(sc8) and 2.08 (sc4). It was>1 for scenarios sc2, sc3, sc4, sc11, and
sc12. This means in case of scenario sc4, that 2.08 Euros are saved
for each invested Euro, whereas only 0.31 Euros per invested Euro
are saved in scenario sc8.
DISCUSSION
We developed two models (DSM and an economic model)
to plan, evaluate, and improve BVD control programs. The
models were applied to the situation in Germany, a country
that is currently in the process of optimizing its BVD control
strategy. Both models may also be applied in other countries.
They can help to design or improve other disease control
Frontiers in Veterinary Science | www.frontiersin.org 8 November 2019 | Volume 6 | Article 406
Gethmann et al. Economic Model of BVD in Germany
TABLE 3 | Estimated market value of cattle of different age classes.
Calves (0–6 months) Young stock (7–24 months) Heifers Cows
Age in months 1 · · · 12 · · · 24 25 26 27 28 29
Mean 304.4 · · · 902.3 · · · 1,616.8 1,673.4 1,729.9 1,855.1 1,913.9 1,972.6 1,451.4
Min 165.1 · · · 489.3 · · · 876.7 907.4 938.0 1,005.9 1,037.8 1,069.6 376.9
1st Qu 276.6 · · · 819.9 · · · 1,469.1 1,520.5 1,571.9 1,685.7 1,739.0 1,792.4 1,260.8
Median 316.2 · · · 937.4 · · · 1,679.7 1,738.4 1,797.1 1,927.2 1,988.2 2,049.2 1,493.8
3rd Qu 339.8 · · · 1,007.4 · · · 1,805.0 1,868.1 1,931.2 2,071.0 2,136.6 2,202.1 1,682.6
Max 358.6 · · · 1,062.9 · · · 1,904.5 1,971.1 2,037.7 2,185.2 2,254.4 2,323.5 1,936.3
TABLE 4 | Total costs (direct and indirect costs) per scenario (million Euros) with
minimum and maximum values.
Scenario Mean Minimum Maximum
sc1 2,258 1,821 3,497
sc2 1,933 1,614 2,540
sc3 1,909 1,602 2,469
sc4 1,413 1,162 2,195
sc5 2,525 2,167 3,139
sc6 3,655 2,966 4,520
sc7 2,511 2,122 3,214
sc8 7,229 5,567 9,128
sc9 2,703 2,308 3,287
sc10 2,680 2,094 3,488
sc11 1,812 1,503 2,402
sc12 1,769 1,430 2,534
sc13 2,747 2,206 3,498
programs and to avoid problems that may be expected in
their course.
Economic Model
We estimated the direct costs of BVD to range from 34 to
402 million Euros per year in Germany, with a mean of 113
million Euros, corresponding to 28.3 million Euros per million
animals. These results fall within the range of estimates that
were previously obtained for other countries. Projected on costs
per million animals, direct BVD costs were estimated at 18–
21 million Euros for Switzerland (36), at 16.3 million Euros for
Norway (37), at 10.3–28 million Euros for the Netherlands (15),
and between 32 million (suckler cows) and 63 million Euros
(dairy cows) for Ireland (38). High costs associated with BVD
infection has led to increased disease in the cattle industry and
to public eradication efforts. Although the German program has
been regarded as successful in recent years (23), it is currently
under revision as eradication has not yet been achieved.
All scenarios that include only “test and cull” strategies, i.e.,
also the current control program, are unlikely to have eradicated
BVD in Germany by 2030. Only scenarios that combine either
antigen or antibody testing with compulsory vaccination (sc5, 8,
9, 13) are likely to reduce the PI prevalence to 0% according to
the model predictions. However, from an economic perspective,
these scenarios are not beneficial.
Scenarios that combine antibody and ear tag testing (sc6, 7, 8,
9) may result in a significantly faster decrease of PI prevalence,
but none of them is economically attractive due to the large
numbers of tests required for surveillance. Scenario sc10 (AbT
only) leads to an increase in PI prevalence and causes higher
costs than sc1. In this case, risk-based surveillancemay reduce the
number of samples, while providing a high sensitivity at the same
time (36). Risk-based categorization of farms could be performed
by taking for example the number of animal movements and the
disease status of the origin of purchased animals into account.
Of all simulated scenarios, only four were found to be
economically attractive, namely scenarios sc2, sc3, sc11, and sc12,
with an NPV of 222, 238, 307, or 337 million Euros, respectively.
Although scenario sc4 has an NPV of 572 million Euros, it must
be assumed that the disease costs will rapidly increase again if
all control measures are abandoned. With scenarios sc11 and 12
(vaccination only), eradication does not appear to be feasible. If
BVD control is stopped before the last PI is removed (see sc4), the
PI prevalence is predicted to level off on the long term at about
0.33%. Previous studies do not advise premature discontinuation
of control efforts, as a mainly seronegative cattle population is
fully susceptible to BVD (39). Abandoning the long-standing
goal of eradicating BVD may lead to necessity of imposing trade
restrictions and, more importantly, to the loss of credibility of
official disease eradication programs.
In summary, scenarios sc2 and sc3 were predicted to be
successful in terms of both, disease eradication and benefit-cost
ratio. However, a major current challenge for BVD eradication
is the unrecognized import of inapparent or subclinical PI
animals. A recent risk assessment showed that BVD is regularly
introduced in the Netherlands through cattle importations
and estimated that 334 cattle herds may become infected per
year (40).
According to our results, the control program currently
implemented in Germany is beneficial (BCR= 1.2). This is in line
with calculations for Ireland (38) and Switzerland (36), which run
similar control programs as Germany. Both groups calculated
a higher BCR (10 and 1.9) than we did. In the Netherlands
(15), where a control program based on bulk milk testing is
in place, the BCR = 1.5 is slightly higher than the one we
calculated for Germany. Other studies came to a negative BCR,
e.g., for Styria, Austria, with a BCR of 0.83 (41). Comparing
our results directly with those of others is difficult as the
control programs are different, the assessment periods vary in
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FIGURE 3 | Direct and indirect costs incurred 2011–2030 in the 13 simulated scenarios.
TABLE 5 | (A) Undiscounted and (B) discounted benefit (B/PVB), indirect cost (IC/PVIC), benefit-cost ratio (BCR), and net value (NV/NPV) of the 13 simulated scenarios (in
million Euros).
Scenario (A) Undiscounted (B) Discounted
B IC BCR NV PVB PVIC BCR NPV
sc1
sc2 1.897 1.573 1,22 324 1.437 1.216 1,18 222
sc3 1.915 1.566 1,24 349 1.449 1.211 1,2 238
sc4 1.413 569 1,1 844 1.097 524 2,09 572
sc5 1.972 2.240 0,92 −268 1.488 1.658 0,9 −170
sc6 1.898 3.295 0,69 −1.397 1.437 2.433 0,59 −996
sc7 1.901 2.154 0,92 −253 1.439 1.633 0,88 −193
sc8 1.976 6.947 0,52 −4.971 1.491 4.837 0,31 −3.346
sc9 1.978 2.423 0,87 −445 1.492 1.785 0,84 −293
sc10 1.831 2.253 0,93 −423 1.388 1.710 0,81 −322
sc11 1.674 1.229 1,95 445 1.266 959 1,32 307
sc12 1.785 1.296 1,51 489 1.351 1.014 1,33 337
sc13 1.934 2.424 0,94 −490 1.458 1.772 0,82 −314
The discounting rate is 3%.
time and duration, and the cattle structure (e.g., herd structure,
trade patterns and animal density) may not be comparable.
A recent review has only identified four countries (Norway,
Ireland, France and Switzerland), where the implementation of
BVD mitigation activities appeared economically justified after a
specific period (16).
Disease Spread Model
In scenario sc1, BVD reaches an endemic status with a
PI prevalence of at least 0.9%. Over the study period,
the PI prevalence was predicted to decrease slightly and
no steady state was reached within the projected period,
although the rate of reduction was very small. Most
probably, this is due to fact that the disease transmission
rates between animals and farms were estimated rather
low, although they were based on values obtained from
literature (32).
In scenario sc4, we observed a rapid increase of the PI
prevalence up to 0.75% just after stopping BVD control, before it
decreases and levels off at about 0.33%. The initial increase of the
PI prevalence is due to the high number of naïve animals at the
end of the control program. In the following years, the number
of animals recovered from transient infection increases and the
number of PI animals decreases until a steady state is reached. In
contrast to sc1, the PI prevalence is lower, probably because in
sc1 no steady state is reached.
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Compared to real life data, the initial PI prevalence in theDSM
was three times higher (1.2 vs. 0.4%) (Figure 4). To explain this
phenomenon, it has to be taken into account that (i) reliable data
from the HIT database were not available until mid-2011 and (ii)
in reality, several federal states had already implemented different
types of voluntary control programs in 2011. Hence, the reported
prevalence at the animal and farm level in previous years does not
necessarily reflect a baseline scenario (without BVD control), but
rather a heterogeneous situation. Compared with studies carried
out prior the start of any control program, e.g., 2.1% in Lower
Saxony, Germany (42) or 0.8–1.3% in Switzerland (9, 11, 43), the
assumed PI prevalence of 1.2% in the DSM seems realistic.
Previous studies revealed BVD seroprevalences of 64–97%
in Germany (44), 57.6% in Switzerland (45), and 33–54% in
Belgium (46, 47). Compared with these studies, the antibody
prevalence of 47% in the DSM seems to be realistic.
Compared with real data obtained from the HIT database,
the reduction in PI prevalence seems to be predicted in a rather
realistic fashion by scenario sc3, with the only difference that the
PI prevalence was reduced to 0.01% in the first quarter of 2017
in reality, while this prevalence level will not be reached until
2024 according to the model prediction (Figure 4). This may be
due to the fact that (i) the initial PI prevalence in scenario sc3 is
three times higher than in reality, and (ii) we did not simulate
further effects in the DSM, e.g., additional measures carried out
by the farmers.
Scenarios that include only ear tag testing (sc2, sc3), only
AbT (sc10) or a combination of both (sc6, sc7) will not lead to
BVD eradication. Regarding scenarios sc2 and sc3, the reasons
are imperfect tests, the continuous importation of PI animals,
delayed removal of PI animals, and failure to take transient
infections into account (23).
In scenario sc10, the number of PI animals increased after
switching from ear tag to antibody testing only. This confirms
experiences made in Switzerland in 2012/2013 (https://www.
infosm.blv.admin.ch/public/). Hence, in terms of PI prevalence,
this option is worse compared to ear tag testing (sc2, 3) Only
scenarios that combine vaccination with either ear tag (sc5) or
AbT (sc13) or both (sc8, sc9) are expected to lead to eradication
according the modeling results. All scenarios that include AbT
are predicted to lead to an unexpectedly high number of blood
antigen tests. This is due to the fact, that, according to German
BVD regulation, all cattle in a farm are subjected to a virus
isolation test to detect viremic animals if an animal is confirmed
antibody positive. Furthermore, maternal BVD antibody titers
are still high enough to be detectable in calves until the age of
9 months. This can explain why so many animals (tested at the
age of 7–18 months) were antibody positive in the DSM and
why strategies that include AbT are so effective in reducing the
PI prevalence. However, in reality, the number of antigen tests
may be substantially lower, probably because animals subjected
to AbT are older than 7 months. Moreover, it seems unlikely that
all animals of a farm will be tested if a single BVD-positive result
is obtained in this herd.
Other studies on the spread of BVD and the effect of different
control strategies were published for Scotland (48), Ireland (49),
and Italy (50). Nevertheless, the authors used other approaches to
model disease spread or tested different control strategies. Tinsley
FIGURE 4 | Comparison of the PI prevalence in reality (source: HIT, blue circles, left axis) and simulated in the DSM, scenario sc3 (red stars, right axis).
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et al. (48) compared only trade restrictions, using a network
model. Thulke et al. (49) tested the change from the current
control system (ear tag testing), which is similar to the German
strategy, to serological testing. They also included additional
factors, e.g., difficulties in changing the strategy. Iotti et al. (50)
used a more general approach in analyzing a random or targeted
removal of farms from the network. These models and the results
obtained with them can therefore not be compared directly with
our findings.
Gross Margin Analysis
The sensitivity analysis showed that the economic model was
most sensitive to alterations in the parameters associated with
production losses. The GMA revealed a mean economic impact
of 56 Euros per TI dairy cow, 8 Euros per heifer and 5 Euros
per calf and thus falls within the range of previous studies: Two
worldwide reviews quote the economic impact of BVD as 0.4–
585 Euros (1) or 0–621 Euros per animal (2). Losses per cow and
year were estimated at 56-133 Euros for France (51), 9.2 Euros
for Norway (37) and 75.5–79.1 Euros for Switzerland (14). In
Bavaria, losses were estimated at 40 Euros per TI in a lactating
cow, 25 Euros per TI in a non-lactating cow and 25 Euros per
young stock or heifer (52). In the Netherlands, the production
losses per milking cow due to BVD were estimated to range
from 19 to 384 Euros per milking cow, with 72 Euros as the
most likely value (53). However, these costs included a biannual
vaccination of all cows in the herd against BVD and further
actions that had to be taken by a farmer to obtain a BVD-free
status for the herd. In general, reproduction losses associated with
BVD may vary greatly and it is difficult to compare them for
different population sizes, herd, and animal-specific conditions
and periods.
Limitations
The disease spread model (DSM) was designed to model the
disease spread via animal trade. Each farm can sell and buy
from all other farm, which might promote the spread of the
virus and thus lead to an overestimation of the number of
affected farms. Also, the model simulates the continuous influx
of a certain proportion of PI (2% of imported animals). The
assumed influx represents a worst-case scenario, which may not
necessarily reflect the true current situation. However, Germany
is not entitled to additional guarantees of BVD-freedom if cattle
are imported from other EU member states, so an influx of PI
animals through cattle trade with farmers in other EU member
states is possible. If and when Germany may achieve freedom
from BVD with a smaller number of imported PI animals
will have to be analyzed in a future study. Moreover, virus
spread by people (e.g., animal traders, veterinarians, farmers)
is not taken into account in the model, which might lead to
an underestimation of the PI incidence. We also had to make
some simplifications in the model: We did not consider different
(combinations of) BVD vaccines, but simulated only the use
of a single vaccine with “standard” efficacy. We also assumed
that PI calves do not receive maternal antibodies. This should
have no influence on the model, since there was only a small
number of PI calves. On the other hand, serological testing of
calves with maternal antibodies leads to false-positive test results
and consequently to the virological testing of the whole herd
with a consequence of a massive overestimation of the number
of tests.
A sensitivity analysis was carried out for several parameters,
e.g., population size, transmission rate, time lag until retesting,
vaccination efficacy (29, 30). When we compared the output
of the model with the data available from the German
cattle trade database, we observed similar trade patterns
and age distributions. Socio-economic or animal welfare
aspects as well as trade benefits that may arise from a
BVDV-free status as well as possible future developments in
European legislation on BVD control were beyond the scope
of this study. Increased biosecurity in terms of quarantine
in combination with testing imported animals in quarantine
in the farm of destination may decrease the risk of virus
spread. The PI prevalence might be reduced accordingly
in all scenarios that include control measures. However,
enhanced biosecurity measures were not taken into account in
our model.
In conclusion, we modeled the spread of BVDV with and
without control measures and calculated the economic impact
of the disease and its control using data from Germany. Our
analysis showed that within the given limitations, only scenarios
with a combination of testing and compulsory vaccination will
lead to eradication. However, these scenarios are not beneficial
from an economic perspective. The currently implemented
eradication program is likely to reduce the PI prevalence
to a very low value close to 0 % at a reasonable cost-
benefit ratio.
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